Concerns remain about the definition of a high risk population who can benefit from low-dose computed tomography screening programs. In this paper, the authors present a promising tool to optimize lung cancer screening in a high-risk population using a serum microRNA signature (miR-Test). The area under the ROC curve of test is 0.85 (95% CI = 0.78 to 0.92).
You are here:
miR-Test: A Blood Test for Lung Cancer Early Detection
Source: Journal of the National Cancer Institute
Keywords:
Author(s): Francesca Montani, Matteo Jacopo Marzi, Fabio Dezi, Elisa Dama, Rose Mary Carletti, Giuseppina Bonizzi, Raffaella Bertolotti, Massimo Bellomi, Cristiano Rampinelli, Patrick Maisonneuve, Lorenzo Spaggiari, Giulia Veronesi, Francesco Nicassio, Pier Paolo Di Fiore and Fabrizio Bianchi
